You are here
The purpose of the Policy is to outline the processes by which IHPA adjusts for instability in the year-on-year price weights and adjustments.
The purpose of the Assessing Materiality of Changes Proposed to the National Pricing Model document is to outline the process IHPA follows when assessing the materiality of proposed changes to the national pricing models such as the introduction of new adjustments or alternative pricing policy approaches.
There is a growing discussion in Australia and internationally about the need to increase focus on delivering value-based health care with a focus on patient outcomes and experience.
IHPA’s Pricing Guidelines and the National Health Reform Agreement include provisions for IHPA to consider the impact on its work of evidence‑based, effective new technologies and innovations in models of health care.
The IHPA Data Access and Release Policy (formerly Information Release Policy) outlines the principles and processes adopted by IHPA in the discretionary access and release of data under the National Health Reform Agreement and the National Health Reform Act 2011.
The purpose of the Management of Confidential Jurisdictional Information Protocol is to advise jurisdictions of the processes and controls adopted by IHPA in managing confidential jurisdictional information as part of its rolling Three Year Data Plan.
A jurisdiction may request IHPA to consider any legitimate and unavoidable costs in the delivery of public hospital services. The purpose of this Framework is to assist jurisdictions in making submissions to IHPA on this issue, to layout the process which IHPA will follow in assessing submissions, and the process to determine adjustments to the NEP.
This Framework outlines the processes to investigate cross-border and cost-shifting disputes following a request by a health minister to ensure the timely, equitable and transparent management of these disputes.
The Impact of New Health Technology Framework (the Framework) outlines the process by which IHPA, via its Clinical Advisory Committee (CAC), will monitor and review the impact of new health technologies on the existing classifications in order to accurately account for them in the pricing of public hospital services.
In consultation with the CAC, IHPA will:
The National Health Reform Act 2011 (the Act), section 131(1)(f), provides that IHPA will determine the public hospital functions that are to be funded in the states and territories by the Commonwealth, except where otherwise agreed between the Commonwealth and a state or territory.
The Independent Hospital Pricing Authority (Pricing Authority) is established under the National Health Reform Act 2011 (Cth) (the Act), and by virtue of Section 131(1) of the Act is invested with the following functions relevant to this National Efficient Price (NEP) Determination 2019-20 (Determination):
The Independent Hospital Pricing Authority (Pricing Authority) is established under the National Health Reform Act 2011 (Cth) (the Act), and by virtue of section 131(1) of the Act is invested with the following functions relevant to this 2019-20 National Efficient Cost Determination (Determination):